The patents cover the various properties of Protectan CBLB612 and related compounds, including composition of matter and methods of use for protecting against apoptosis.
Protectan CBLB612 is a synthetic agent that acts as a potent stimulator of hematopoietic stem cell proliferation and mobilisation to peripheral blood, as demonstrated in both mice and non-human primates.
Cleveland BioLabs chief operating officer Yakov Kogan said that it was the first set of patent approvals for CBLB612.
“We have been progressing well with patent examination in various geographies and we hope to continue receiving grant notifications from different jurisdictions over the coming months,” Kogan said.
Cleveland BioLabs has signed a licensing agreement for CBLB612 with Zhejiang Hisun Pharmaceutical in September 2009, which granted Hisun exclusive rights to develop and commercialise CBLB612 in China in exchange for $1.65m in upfront product development payments, as well as a 10% royalty on any future sales.